Bli medlem
Bli medlem

Du är här

2020-10-28

BioArctic's partner Eisai to present latest data on BAN2401 at CTAD conference

During the conference, Eisai will hold four presentations and present new information from all three on-going clinical studies with the investigational anti-amyloid beta (Aβ) protofibril antibody BAN2401;

  • The first will cover clinical study design and initial screening results of the newly initiated Phase 3 clinical study AHEAD 3-45 in individuals with preclinical (asymptomatic) Alzheimer's disease; 
  • The second will cover baseline characteristics of currently enrolled participants in the ongoing Phase 3 Clarity AD study in early Alzheimer's disease patients;
  • The third will cover results from the latest analysis of amyloid-related imaging abnormalities-edema (ARIA-E) from the Phase 2b core and open-label extension study conducted in early Alzheimer's disease patients;
  • The fourth will cover a preliminary analysis of the effect of BAN2401 on amyloid-levels in the brain and ARIA-E findings observed during the first 12-month treatment period of the ongoing open-label extension of the Phase 2b study. 

Asset in Topic/Planned Date and Time(Eastern Standard Time)
Development,
Session Number
BAN2401 The AHEAD 3-45 Study of BAN2401 in Preclinical Alzheimer's
OC 2 Disease: Study Design and Initial Screening Results
November 4 (Wednesday) 10:00 - 10:15AM (live session)
11:25 - 11:40 AM, Live Q&A of oral communications
BAN2401 Baseline Characteristics for Clarity AD: A Phase 3 Placebo
OC 10 -Controlled, Double-Blind, Parallel-Group, 18-Month Study
Evaluating BAN2401 in Early Alzheimer's Disease
November 4 (Wednesday) 1:00 PM (on demand)
BAN2401 BAN2401 and ARIA-E in Early Alzheimer's Disease:
OC 14 Pharmacokinetic/Pharmacodynamic Time-to-Event Analysis
from the Phase 2 Study in Early Alzheimer's Disease
November 5 (Thursday) 9:45 - 10:00 AM (live session)
11:15 - 11:30 AM, Live Q&A of oral communications
BAN2401 Preliminary Analysis of BAN2401 Effects on Brain Amyloid
LB 24 and ARIA-E Findings Over 12 Months of Treatment in the
Open-Label Extension of the Phase2b Study BAN2401-G000-201
in Subjects with Early Alzheimer's Disease
November 7 (Saturday) 12:10 AM - 12:25 PM (live session)
12:25 - 12:50 PM, Live Q&A of late breakers

---
This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval.

This information was submitted for publication at 08:00 am CET on October 28, 2020.

Författare BioArctic

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.